The global hepatitis B therapeutic drug market is anticipated to grow with a moderate CAGR during the forecast period, i.e., 2021-2029. The growth of the market can be attributed primarily to the growing number of individuals who are infected by the hepatitis B virus, along with the need amongst the individuals to cure the viral infection.
Hepatitis is referred to as an inflammatory condition of the liver and is commonly caused by a hepatitis virus. The most common hepatotropic viruses that cause hepatitis are hepatitis A, B, C, D, and E. Hepatitis B is caused by Hepatitis B virus (HBV) which belongs to the viral family Hepadnaviridae. Viral hepatitis B infections are diagnosed by the use of virus testing diagnostic kits, whereas for non-viral infections, blood tests, liver ultrasound or liver biopsy tests are performed. Recently, with the advancements in medical sciences, rapid testing kits are also being used widely by medical practitioners for the detection of the disease. The treatment of hepatitis B is done by the use of the hepatitis B vaccine or through anti-viral drugs. Though, several players are still in search of developing a new cure for hepatitis B, and few of them are in the development of new drugs and medicines for hepatitis B, as the treatment developed for hepatitis B doesn’t totally eradicate the virus from the human body. Hepatitis B is transmitted commonly through direct contact with infected blood, especially during unsterile healthcare practices, or while giving birth to the newborn by the mother, who is a hepatitis B carrier. Hepatitis B is also transmitted through unprotected sexual intercourse or contact with bodily fluids. Hepatitis B infection in human beings can be either acute or chronic. The United States Food and Drug Administration (FDA) has approved eight different treatment options for the treatment of chronic hepatitis B. These include treatment with tenofovir alafenamide, adefovir, entecavir, pegylated interferon, tenofovir disoproxil, telbivudine, alpha-interferon, and lamivudine.
The global hepatitis B therapeutic drug market is thriving on account of the growing need for a drug that can completely cure the virus infection, backed by the growing incidences of chronic hepatitis B infection globally, along with the growing awareness amongst individuals for the treatment of the disease. According to the statistics by the World Health Organization (WHO), around 240 million people globally are infected with chronic hepatitis B virus. Moreover, the statistics also stated that a cumulative 20 million deaths are anticipated to occur between 2015 and 2030. Further, the growing concern for liver cancer globally is also anticipated to contribute to the market growth in the coming years. The market is segmented by product type into hepatitis B vaccine, and anti-viral drugs. The anti-viral drugs segment is further bifurcated into tenofovir (VIREAD), lamivudine (EPIVIR), entecavir (BARACLUDE), telbivudine (TYZEKA), and adefovir (HEPSERA). Among these segments, the tenofovir (VIREAD) segment is projected to hold a significant market share by the end of 2021. Two combinations of tenofovir are used widely for the treatment of chronic hepatitis B, namely tenofovir disoproxil fumarate (chemical formula: C19H30N5O10P; sold under the trade name VIREAD, developed by Gilead Sciences, Inc.), and tenofovir alafenamide (chemical formula: C21H29N6O5P; sold under the brand name VEMLIDY, developed by Gilead Sciences, Inc.). These anti-viral drugs are used in combination with other antiretrovirals for the treatment of hepatitis B and are listed on the list of essential medicines of the World Health Organization. CLICK TO DOWNLOAD SAMPLE REPORT
The spread of communicable diseases is a major concern amongst nations worldwide. To fight the spread of such diseases, the United Nations has outlined the 2030 Agenda for Sustainable Development, which further lays down 17 sustainable development goals, focused on different challenging aspects. Viral hepatitis, which is an international public health challenge, has raised the focus of government bodies, such as the World Health Organization (WHO), for formulating strategies that can help to achieve the laid down targets for 2030. As such, the WHO has defined a set of five strategic decisions to promote drug manufacturers globally and to support countries in spreading the awareness of communicable disease.
Backed by the increasing support of the governmental bodies, as well as the support of the government of nations across the world, the drug manufacturers in the pharmaceutical industry are significantly expanding their focus on the research and development of new drugs that can help to cure hepatitis B, which is anticipated to drive the market growth. Additionally, significant spending by the government of nations to promote research and the rising awareness amongst the individuals for the early detection of the viral infection are some of the additional factors anticipated to drive the growth of the global hepatitis B therapeutic drug market during the forecast period.
Although there is a significant amount of research and development happening in the field of developing novel drugs and therapies for the cure of hepatitis B, yet the unavailability of a proper healthcare infrastructure in several nations where the prevalence of the viral infection is significantly high, is one of the major factors anticipated to hamper the market growth. Moreover, the long-standing process for the approval of a novel drug, and the high cost of treatment in several developing nations are some of the additional factors anticipated to lower the growth of the global hepatitis B therapeutic drug market in the coming years.
The coronavirus pandemic, which has impacted businesses worldwide, also had its impact on the global hepatitis B therapeutic drug market. Owing to the COVID-19 pandemic, drug manufacturing companies have shifted their focus on the development of a novel vaccine for the prevention and treatment of the SARS-CoV2 virus. Furthermore, as the number of patients visiting the hospitals for the treatment of hepatitis B was very less, those companies who were into the phase of the clinical trials of their vaccine subjects, couldn’t continue with their research process, which further impacted the progress of research in the development of the novel drug. However, the operators operating in the development of the novel drug for the cure of hepatitis B, are anticipating that over the next few months, as the pandemic situation comes under control, the process for the development of novel drug would significantly be paced up, which in turn would contribute to the growth of the global hepatitis B therapeutic drug market.
Our in-depth analysis of the global hepatitis B therapeutic drug market includes the following segments:
On the basis of regional analysis, the global hepatitis B therapeutic drug market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa regions.
Among the market in these regions, the Asia Pacific hepatitis B therapeutic drug market is projected to hold the largest market share by the end of 2029 owing to the increasing prevalence of the viral disease in nations, such as China, Mongolia, Korea, Vietnam, and others, along with the growing need of the nations to find a cure for the viral disease. Alternatively, the market in North America is projected to grow with the highest CAGR during the forecast period owing to the presence of several key players in the region who are increasingly focusing on developing novel therapies and drugs for the treatment of hepatitis B.
The global hepatitis B therapeutic drug market is further classified on the basis of region as follows:
FREQUENTLY ASKED QUESTIONS
Increasing prevalence of hepatitis B infections globally is one of the major factors driving the market growth.
The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2021-2029.
The major companies in the market are GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi-aventis Groupe, F. Hoffmann-La Roche Ltd., India Immunologicals Ltd., Merck & Co., Inc., Novartis AG, and others.
The company profiles are selected based on the revenues generated from segments, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market in the Asia Pacific is projected to hold the dominating share by the end of 2029, backed by the rising prevalence of the viral disease in China, Korea, Mongolia, Vietnam, and others.
The hepatitis B therapeutic drug market is segmented by product type, therapy, route of administration, distribution channel, and by region.
Lack of proper healthcare infrastructure in several developing nations around the globe is one of the major factors estimated to act as barriers to the growth of the market.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization